Clinical Trial

REGEND001 Autologous Basal Layer Stem Cell Transplantation for Bronchiectasis: A Translational Application Study

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This clinical trial aims to evaluate the safety and efficacy of REGEND001, an autologous basal layer stem cell transplantation therapy, in patients with chronic structural lung disease (bronchiectasis). The treatment involves harvesting bronchial basal layer stem cells from the patient, expanding them ex vivo, and reintroducing them via bronchoscopic infusion to repair damaged lung tissue.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-05-22; most recent amendment 2026-07-18.
Status change: Not Yet Recruiting → Recruiting 2026-07-17
Trial Details
NCT Number NCT06987214
Lead Sponsor Ruijin Hospital
Conditions Bronchiectasis Adult
Enrollment 10 participants
Start Date 2025-06-18
Primary Completion 2029-05-30 (estimated)
Study Completion 2029-05-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-28